CL097 hydrochloride|西域试剂

CL097 hydrochloride,99.51%

产品编号：Bellancom-128799A| 分子式：C₁₃H₁₅ClN₄O| 分子量：278.74

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-128799A		￥2400.00	杭州北京（现货）
Bellancom-128799A		￥3600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CL097 hydrochloride

产品介绍

CL097 是一种有效的 TLR7 和 TLR8 激动剂，可在巨噬细胞中诱导促炎细胞因子。CL097 诱导 NADPH 氧化酶启动活性，导致 fMLF 刺激的 ROS 产生增加。

生物活性

CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production.

体外研究

CL097 induces activation of NF-κB at 0.1 μM in TLR7 transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells.
CL097 induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils and suggest that p38 MAPK, ERK1/2, protein kinase C, and Pin1 control this process. CL097 induces the phosphorylation of p47phox on specific sites and enhances fMLF-induced p47phox phosphorylation.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Neutrophils
Concentration:	0, 0.5, 2.5, 5, and 10 μg/mL
Incubation Time:	Pretreated for 30 minutes
Result:	Induced phosphorylation of p47phox on specific sites in a concentration-dependent manner.

体内研究
(In Vivo)

CL097 and CD40 agonist stimulation induces efficient diabetogenic Cytotoxic T lymphocyte (CTL) function in NOD mice. CL097 (5 mg/kg, s.c.) alone causes a modest specific lysis of the target peptide (∼25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female 8.3 NOD mice (5-6 weeks old)
Dosage:	5 mg/kg
Administration:	Injected s.c.
Result:	Caused a modest specific lysis of the target peptide (∼25%).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female 8.3 NOD mice (5-6 weeks old)
Dosage:	5 mg/kg
Administration:	Injected s.c.
Result:	Caused a modest specific lysis of the target peptide (∼25%).

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female 8.3 NOD mice (5-6 weeks old)
Dosage:	5 mg/kg
Administration:	Injected s.c.
Result:	Caused a modest specific lysis of the target peptide (∼25%).

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (358.76 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5876 mL	17.9379 mL	35.8757 mL
5 mM	0.7175 mL	3.5876 mL	7.1751 mL
10 mM	0.3588 mL	1.7938 mL	3.5876 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (8.97 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.97 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.97 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.97 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.97 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (8.97 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。